Results 181 to 190 of about 310,541 (335)
ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli +17 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source
SERCA in heterogeneity of diastolic dysfunction in post-infarction heart failure with reduced ejection fraction [PDF]
, 2019 Masao Endoh
openalex +1 more source
Preoperative echocardiography as a predictor of spinal anesthesia-induced hypotension in older patients with mild left ventricular diastolic dysfunction: a retrospective observational study [PDF]
Eun Ji Park +8 more
openalex +1 more source
Isolated diastolic dysfunction of right ventricle: stress-induced pulmonary hypertension: Table 1— [PDF]
, 2008 Réka Faludi +6 more
openalex +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
Pulmonary Hypertension in Elderly Patients with Diastolic Dysfunction and Preserved Ejection Fraction [PDF]
, 2012 Majid Afshar, F. Collado, Rami Doukky
openalex +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy. [PDF]
J Mol Cell Cardiol PlusChan JSF +16 more
europepmc +1 more source